Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use AFSTYLA safely and effectively. See full prescribing information for AFSTYLA. AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] Lyophilized Powder for Solution for Intravenous InjectionInitial U.S. Approval: 2016
Medication labelWhy this: Advisory · dailymed-other
AFSTYLA, Antihemophilic Factor (Recombinant), Single Chain is a recombinant, antihemophilic factor indicated in adults and children with hemophilia A (congenital Factor VIII deficiency) for: On-demand treatment and control of bleeding episodes, Routine prophylaxis to reduce the frequency of bleeding episodes, Perioperative management of bleeding. Limitation of Use AFSTYLA is not indicated for the treatment of von Willebrand disease.
- generic_name
- antihemophilic factor, human recombinant
- brand_name
- water
- product_names
- ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT, water
- ndc
- 69911-474, 69911-475, 69911-476, 69911-477, 69911-478, 69911-480, 69911-481, 69911-474-02, 69911-484, 69911-484-01, 69911-765, 69911-765-83, 69911-475-02, 69911-485, 69911-485-01, 69911-476-02, 69911-486, 69911-486-01, 69911-477-02, 69911-487, 69911-487-01, 69911-765-84, 69911-478-02, 69911-488, 69911-488-01, 69911-480-02, 69911-490, 69911-490-01, 69911-481-02, 69911-491, 69911-491-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en